Gilead Sciences and Vir Biotechnology have significantly expanded their strategic research and development alliance through a newly finalized licensing agreement…
Read More
How the Grand Canyon could have lost 1 billion years of geologic history
Recent research published in the journal Geology on August 17, 2026, by a team led by Dr. Thomas Gernon of…
Read More
Shionogi Expands Rare Disease Portfolio With $2 Billion Acquisition of IntraBio and Flagship Drug Aqneursa
Japanese pharmaceutical major Shionogi has announced a definitive agreement to acquire IntraBio in a multibillion-dollar transaction valued at $2 billion.…
Read More
MSD Strengthens Oncology Pipeline with Multi-Billion-Dollar Licensing Deal for Shanghai-Based SciBrunch Therapeutics KRAS Inhibitor SPR2015
In a strategic move to fortify its oncology portfolio against looming patent expirations, MSD—known as Merck & Co. in the…
Read More
Roche Deepens AI and Small Molecule Strategy with Multi-Billion-Dollar Partnerships in Oncology and CVRM
Swiss pharmaceutical giant Roche, acting through its subsidiary Genentech, has entered a blockbuster agreement with Earendil Labs, committing up to…
Read More
Roche and Dualitas Therapeutics Ink Billion-Dollar Partnership to Advance Next-Generation Bispecific Antibodies in Immunology and Inflammation
In a landmark agreement that underscores the surging therapeutic potential of proximity biology, Swiss pharmaceutical giant Roche has joined forces…
Read More
BeOne Medicines Invests $300 Million to Expand Hopewell, New Jersey Manufacturing and Research Operations, Pushing Total US Investment Past $1 Billion
BeOne Medicines is significantly bolstering its presence in the United States with a substantial $300 million investment earmarked for the…
Read More
Eli Lilly Commits Up to $3.8 Billion to Acquire AtaiBeckley, Betting on the ‘God Molecule’ 5-MeO-DMT for Transformative Mental Healthcare
Indianapolis, IN – Pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire AtaiBeckley, a clinical-stage biotechnology company focused…
Read More
Sample ages bolster a rising tide doubting a singular 3.9 billion-year-old lunar cataclysm
The long-held theory of a singular, cataclysmic bombardment of the inner solar system, often referred to as the Late Heavy…
Read More
Samsung Biologics to Acquire PolyPeptide Group for SFr1.46 Billion, Expanding Peptide Therapeutics and CDMO Capabilities
Samsung Biologics has announced its intent to acquire PolyPeptide Group, a leading contract development and manufacturing organization (CDMO) specializing in…
Read More
